Safety profile of extended-release Niacin/Laropiprant in patients with dyslipiclemia

被引：0
|
作者：
McKenney, James
Bays, Harold
Koren, Michael J.
Ballantyne, Christie
Maccubbin, Darbie
Mitchel, Yale
Betteridge, Abigaile
Kuznetsova, Olga
Sapre, Aditi
Sisk, Christine McCrary
Paolini, John F.
机构：
[1] Virginia Commonwealth Univ, Richmond, VA USA
[2] Merck Res Labs, Rahway, NJ USA
来源：
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2008年 / 51卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A334 / A334
页数：1
相关论文
共 50 条
  • [21] Following Stable Therapy with Extended Release Niacin/Laropiprant, Continued Extended Release Niacin/Laropiprant Use Reduced Flushing versus Extended Release Niacin Alone in Dyslipidemic Patients
    Chen, Fabian
    Maccubbin, Darbie
    Anderson, Jennifer Weimer
    Sisk, Christine McCrary
    Kher, Uma
    Olsson, Anders
    Bays, Harold E.
    CIRCULATION, 2011, 124 (21)
  • [22] Lipid-altering efficacy of extended-release niacin/laropiprant in dyslipidaemic patients with metabolic syndrome
    Bays, H. E.
    Maccubbin, D. L.
    Shah, A. K.
    Lin, J.
    Sisk, C. M.
    Paolini, J. F.
    DIABETOLOGIA, 2008, 51 : S558 - S558
  • [23] Extended-Release Niacin/Laropiprant Effects on Lipoprotein Subfractions in Patients with Type 2 Diabetes Mellitus
    Bays, Harold
    Giezek, Hilde
    McKenney, James M.
    O'Neill, Edward A.
    Tershakovec, Andrew M.
    METABOLIC SYNDROME AND RELATED DISORDERS, 2012, 10 (04) : 260 - 266
  • [24] Extended-release niacin/laropiprant for lipid management: observational study in clinical practice
    Steinhagen-Thiessen, E.
    Daenschel, W.
    Buffleben, C.
    Smolka, W.
    Pittrow, D.
    Hildemann, S. K.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2013, 67 (06) : 527 - 535
  • [25] Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia
    Hu, Miao
    Yang, Ya-Ling
    Masuda, Daisaku
    Yamashita, Shizuya
    Tomlinson, Brian
    DISEASE MARKERS, 2015, 2015
  • [26] Extended-Release Niacin/Laropiprant Improves Overall Efficacy of Postprandial Reverse Cholesterol Transport
    El Khoury, Petra
    Waldmann, Elisa
    Huby, Thierry
    Gall, Julie
    Couvert, Philippe
    Lacorte, Jean-Marc
    Chapman, John
    Frisdal, Eric
    Lesnik, Philippe
    Parhofer, Klaus G.
    Le Goff, Wilfried
    Guerin, Maryse
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (02) : 285 - 294
  • [27] Effects of extended release niacin/laropiprant, laropiprant, extended release niacin and placebo on platelet aggregation and bleeding time in healthy subjects
    Lai, Eseng
    Schwartz, Jules I.
    Dallob, Aimee
    Jumes, Patricia
    Liu, Fang
    Kraft, Walter K.
    Royalty, Jane
    Chodakewitz, Jeffrey A.
    Sisk, Christine Mccrary
    Radziszewski, Waldemar
    Wagner, John A.
    PLATELETS, 2010, 21 (03) : 191 - 198
  • [28] Flushing profile of extended release niacin/laropiprant versus gradually titrated NiaspanTM in patients with dyslipidemia
    Koren, Michael J.
    Maccubbin, Darbie
    Davidson, Michael
    Macconell, Geraldine
    Mallick, Madhuja
    Sisk, Christine McCrary
    Ballantyne, Christie
    Paolini, John F.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2008, 51 (10) : A324 - A325
  • [29] Extended-release niacin/laropiprant lipid-altering consistency across patient subgroups
    Bays, H.
    Shah, A.
    Dong, Q.
    Sisk, C. McCrary
    Maccubbin, D.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (04) : 436 - 445
  • [30] Relative safety of extended-release niacin versus other niacin formulations
    Alsheikh-Ali, AA
    Abourjaily, HM
    Kares, RH
    CIRCULATION, 2004, 110 (17) : 813 - 814
12345